Phosphorex and Dolomite Microfluidics Partner to Accelerate Lipid Nanoparticle (LNP) Development
Hopkinton, Mass., June 1, 2021 — Phosphorex, Inc., a leading contract development and manufacturing organization specializing in particle-based formulation of drug products, and Dolomite Microfluidics, a leading developer of particle systems for drug delivery, are pleased to announce their partnership to establish unique capabilities in drug and vaccine development. The partnership will feature the installation of Dolomite’s next generation Automated Nanoparticle (ANP) System in Phosphorex’s state-of-the-art laboratories, located in Hopkinton, MA, enabling the rapid development of novel nanoparticle formulations to meet a wide range of specifications.
Liposomes, lipid nanoparticles and polymeric nanoparticles have become indispensable tools for non-viral delivery of a variety of therapeutics, especially nucleic acids, including mRNAs for vaccines to fight cancer and infectious diseases such as COVID-19. These nanoparticles can enhance transfection efficiency, stability, safety, and efficacy of RNA therapeutics and vaccines. Dolomite’s ANP System will enhance the services that Phosphorex can provide to its customers, including rapid development of prototype formulations and optimization, scale-up and generation of GLP materials to support pre-clinical trials. In addition, Phosphorex will act as a demonstration lab for Dolomite, and offer training and technical support to help customers to advance their RNA programs from the discovery to the clinical development stage.
Richard Gray, Commercial Director at Dolomite Microfluidics, said: “Phosphorex is a leader in drug delivery and nanoparticle formulations, and we are excited to collaborate with them to develop and scale-up their clients’ RNA programs. To date, our solutions serve thousands of customers in over 50 countries around the world, working in fields as diverse as academia, biotechnology, drug discovery, food and cosmetics, and the petrochemical and pharmaceutical industries.”
Dr Bin Wu, Founder, President and CEO of Phosphorex, commented: “We are very happy about the partnership with Dolomite Microfluidics. Although we can use the ANP System for many different applications, we are especially excited about its application to formulate RNA-based therapeutics and vaccines. Several RNA-based therapeutics have so far been approved by the FDA for the treatment of otherwise hard-to-treat diseases, and two COVID-19 vaccines demonstrating high efficacy and safety profile are playing a major role in ending the pandemic. I truly believe this collaboration can help fully harness the potential of RNA technologies to treat infectious diseases, cancer and many other difficult-to-treat diseases.”